Artykuły udostępnione publicznie: - Andrew P MontgomeryWięcej informacji
Niedostępne w żadnym miejscu: 8
Late-stage functionalization for improving drug-like molecular properties
NJ Castellino, AP Montgomery, JJ Danon, M Kassiou
Chemical reviews 123 (13), 8127-8153, 2023
Upoważnienia: National Health and Medical Research Council, Australia
Recent scaffold hopping applications in central nervous system drug discovery
TB Callis, TR Garrett, AP Montgomery, JJ Danon, M Kassiou
Journal of Medicinal Chemistry 65 (20), 13483-13504, 2022
Upoważnienia: National Health and Medical Research Council, Australia
An update on late-stage functionalization in today’s drug discovery
AP Montgomery, JM Joyce, JJ Danon, M Kassiou
Expert Opinion on Drug Discovery 18 (6), 597-613, 2023
Upoważnienia: National Health and Medical Research Council, Australia, UK Medical Research …
Tricyclic heterocycles display diverse sensitivity to the A147T TSPO polymorphism
R Sokias, EL Werry, HWA Cheng, JH Lloyd, G Sohler, JJ Danon, ...
European Journal of Medicinal Chemistry 207, 112725, 2020
Upoważnienia: National Health and Medical Research Council, Australia
Strategies for targeting the P2Y12 receptor in the central nervous system
BB Ma, AP Montgomery, B Chen, M Kassiou, JJ Danon
Bioorganic & medicinal chemistry letters 71, 128837, 2022
Upoważnienia: National Health and Medical Research Council, Australia
The discovery of a potent and selective pyrazolo-[2, 3-e]-[1, 2, 4]-triazine cannabinoid type 2 receptor agonist
M Moir, S Lane, AP Montgomery, D Hibbs, M Connor, M Kassiou
European Journal of Medicinal Chemistry 210, 113087, 2021
Upoważnienia: National Health and Medical Research Council, Australia
Synthesis and evaluation of various heteroaromatic benzamides as analogues of–ylidene-benzamide cannabinoid type 2 receptor agonists
M Moir, R Boyd, H Gunosewoyo, AP Montgomery, M Connor, M Kassiou
Tetrahedron Letters 60 (36), 151019, 2019
Upoważnienia: National Health and Medical Research Council, Australia
Synthesis and preclinical evaluation of fluorinated 5-azaindoles as CB2 PET radioligands
A Kallinen, K Mardon, S Lane, AP Montgomery, R Bhalla, DHR Stimson, ...
ACS Chemical Neuroscience 14 (16), 2902-2921, 2023
Upoważnienia: National Health and Medical Research Council, Australia
Dostępne w jakimś miejscu: 14
Computational glycobiology: Mechanistic studies of carbohydrate-active enzymes and implication for inhibitor design
AP Montgomery, K Xiao, X Wang, D Skropeta, H Yu
Advances in protein chemistry and structural biology 109, 25-76, 2017
Upoważnienia: Australian Research Council
Computational characterisation of the interactions between human ST6Gal I and transition‐state analogue inhibitors: insights for inhibitor design
A Montgomery, R Szabo, D Skropeta, H Yu
Journal of Molecular Recognition 29 (5), 210-222, 2016
Upoważnienia: Australian Research Council
Transition state-based ST6Gal I inhibitors: Mimicking the phosphodiester linkage with a triazole or carbamate through an enthalpy-entropy compensation
AP Montgomery, D Skropeta, H Yu
Scientific Reports 7 (1), 14428, 2017
Upoważnienia: Australian Research Council
DYRK1A negatively regulates CDK5-SOX2 pathway and self-renewal of glioblastoma stem cells
B Chen, D McCuaig-Walton, S Tan, AP Montgomery, BW Day, M Kassiou, ...
International journal of molecular sciences 22 (8), 4011, 2021
Upoważnienia: National Health and Medical Research Council, Australia
Design, synthesis and evaluation of carbamate-linked uridyl-based inhibitors of human ST6Gal I
AP Montgomery, C Dobie, R Szabo, L Hallam, M Ranson, H Yu, ...
Bioorganic & Medicinal Chemistry 28 (14), 115561, 2020
Upoważnienia: Australian Research Council
Computer‐aided design of human sialyltransferase inhibitors of hST8Sia III
C Dobie, AP Montgomery, R Szabo, D Skropeta, H Yu
Journal of Molecular Recognition 31 (2), e2684, 2018
Upoważnienia: Australian Research Council
Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia
SL Carey-Smith, MH Simad, K Panchal, C Aya-Bonilla, H Smolders, S Lin, ...
Haematologica 109 (7), 2309, 2024
Upoważnienia: National Health and Medical Research Council, Australia, European Commission …
Sialyltransferase Inhibitors as Potential Anti-Cancer Agents
D Skropeta, C Dobie, AP Montgomery, H Steele, R Szabo, H Yu
Australian Journal of Chemistry 74 (11), 758-766, 2021
Upoważnienia: Australian Research Council
Unlocking therapeutic potential: the role of adamantane in drug discovery
C Dane, GA Cumbers, B Allen, AP Montgomery, JJ Danon, M Kassiou
Australian Journal of Chemistry 77 (8), NULL-NULL, 2024
Upoważnienia: National Health and Medical Research Council, Australia
Synthesis and biological evaluation of selective phosphonate-bearing 1, 2, 3-triazole-linked sialyltransferase inhibitors
C Dobie, AP Montgomery, R Szabo, H Yu, D Skropeta
RSC Medicinal Chemistry 12 (10), 1680-1689, 2021
Upoważnienia: Australian Research Council
Understanding in vitro pathways to drug discovery for TDP-43 proteinopathies
HWA Cheng, TB Callis, AP Montgomery, JJ Danon, WT Jorgensen, YD Ke, ...
International Journal of Molecular Sciences 23 (23), 14769, 2022
Upoważnienia: National Health and Medical Research Council, Australia
Structure-based drug design for TSPO: Challenges and opportunities
M Giladi, AP Montgomery, M Kassiou, JJ Danon
Biochimie, 2024
Upoważnienia: National Health and Medical Research Council, Australia
Informacje na temat publikacji i finansowania automatycznie określa program komputerowy